Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie’s two lead product candidates are once-daiIy IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA filing for Rhopressa™ (netarsudil ophthalmic solution) 0.02% was originally submitted in the third quarter of 2016 and is expected to be resubmitted in January 2017. The second product candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of Rhopressa™ and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a Roclatan™ NDA filing is expected to take place near year-end 2017. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology.
The Buddy Group is a California-based digital engagement agency that strategizes, creates, distributes and manages digital content for brands of all sizes. As a full-service agency, The Buddy Group operates at the convergence point of marketing, storytelling and technology.The Buddy Group provides clients with a wide variety of services including digital strategy, social media account management, UI design, video production, digital distribution and more. Since the agency’s launch in 2005, The Buddy Group has leveraged its expertise in over 200 products launches, deployed across mobile, web and connected television, or as its known by the agency, the Connected14. Learn more about The Buddy Group at www.thebuddygroup.com/
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. With almost 3,000 employees, the Group generated revenue of € 909 million in financial year 2013/2014 (to 30 September).
The head office of Carl Zeiss Meditec is in Jena, Germany. The Company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
Carl Zeiss offers innovative solutions for the future-oriented markets Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.
For more information visit our website at: www.meditec.zeiss.com
Chapman University, founded in 1861, is one of the oldest, most prestigious private universities in California. Chapman’s picturesque campus is located in the heart of Orange County—an exciting center of arts, business, science, and technology—and draws outstanding students and faculty from across the United States and around the world.
Deloitte has a single focus: serving our clients and helping them solve their toughest problems. We work in four key business areas—audit, financial advisory, tax, and consulting—but our real strength comes from combining the talents of those groups to address clients’ needs.
DevicePharm is an Irvine, California-based provider of marketing strategy and integrated marketing communications solutions for organizations serving medical professionals and healthcare consumers. Our clients include medical device, biotech, life science, and pharmaceutical firms ranging from investor-backed start-ups to established market leaders.
Fleishman-Hillard International Communications, one of the world’s leading strategic communications firms, has built its reputation on creating integrated solutions that deliver what its clients value most: meaningful, positive and measurable impact on the performance of their organizations. The Fleishman-Hillard Orange County office offers full-service communications to clients in the technology, healthcare, corporate services, clean technology/green energy, and financial services sectors. The firm operates throughout North America, Europe, Asia Pacific, Middle East, Africa and Latin America through its 80 owned offices. For more information, visit the Fleishman-Hillard website at www.fleishmanhillard.com.
Knobbe Martens Olson & Bear, currently the third largest IP firm nationwide, is a law firm practicing exclusively in the area of intellectual property law including patents, trademarks, copyrights, trade secrets, rights of publicity, unfair competition, and related litigation and licensing. Services are provided to clients throughout the United States and the world in a broad spectrum of intellectual property matters.
It started with an idea. Services businesses were difficult to operate, the way people work together was changing, and the right technology was absent. Today, Mavenlink provides enterprise-class Software as a Service (SaaS) that transforms the way services organizations work. With projects, financials, collaboration, resource management, and business intelligence in a single unified environment, teams using Mavenlink are able to connect, collaborate, execute, and thrive like never before.
MicroVention is a rapidly growing medical device company that has pioneered the development of catheter-based, minimally invasive, neuroendovascular technologies that provide therapeutic advantages for cerebral aneurysms and other neurovascular diseases. The Company dedicates significant resources to support Research & Development, with an emphasis on innovative endovascular technologies that provide a meaningful improvement in patient lives.
PricewaterhouseCoopers’ industry-focused professionals deliver assurance, tax, human resources, transaction, performance improvement and IT strategy, planning, and implementation support to clients throughout the globe.
RSM US LLP (formerly McGladrey LLP) is the leading provider of assurance, tax and consulting services focused on the middle market. We guide our clients through complex business challenges by understanding their needs and bringing together the right team to address them. With more than 9,000 people in 86 offices nationwide—and access to more than 38,000 people in over 120 countries through our membership in RSM International—RSM serves clients wherever they do business around the world.
Savills Studley is the leading commercial real estate services firm specializing in tenant representation. Founded in 1954, the firm pioneered the conflict-free business model of representing only tenants in their commercial real estate transactions. The firm is part of London-headquartered Savills plc, the premier global real estate service provider with over 30,000 professionals and over 700 locations around the world. Savills plc is listed on the London Stock Exchange (SVS.L).
Stradling Yocca Carlson & Rauth is a leading business law firm. Known as the “go-to” firm for emerging growth companies in California, Stradling offers an extensive array of legal and advisory services in corporate and securities, complex business litigation, tax, employment, and intellectual property. No law firm has helped launch more companies in Southern California than Stradling.
Teijin Pharma has been marketing a long succession of new products in pharmaceutical and home healthcare businesses based on its product development capacity and expanded alliances with domestic and overseas companies. The company is now focusing its efforts on “Bone and Joint Diseases,” “Respiratory Diseases,” and “Cardiovascular and Metabolic Diseases” as three target categories for product development and services. Through synergistic effects of its two businesses, Teijin Pharma has realized unique solutions that have gone unsurpassed by other companies. Healthcare providers rely on Teijin Pharma with high expectations and trust.
University of California, Irvine is among the fastest-growing UC campuses, is a member of the prestigious Association of American Universities (AAU), and is consistently ranked among the nation’s best universities, public and private. UCI’s goal of promoting diversity among faculty, students, and staff shapes endeavors in teaching, research, and public service.